RxDoctor Payments Data

Susan Pappas, APRN

Psychiatric/Mental Health · Waterbury, CTNPI 1720616246

Payments from drug & device makers

$1,081in general payments, 2019–2025

Across 60 payments — averaging $18.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$391
  • Teva Pharmaceuticals USA, Inc.$158
  • Otsuka America Pharmaceutical, Inc.$144
  • Johnson & Johnson$142
  • Neurocrine Biosciences, Inc.$79
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$77
  • plus $90 from 3 others

What the payments were for

  • Food & beverage$1,081100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,081 in reported general payments places this provider in the 70th percentile of 679 psychiatric/mental health providers in Connecticut.

See all psychiatric/mental health providers in Connecticut

Medicare billing

Part B allowed, 2024
$8,321
Medicare patients
48
Services billed
97

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AustedoDeutetrabenazine15$92,660
Risperdal ConstaRisperidone Microspheres28$58,673
VraylarCariprazine Hcl29$49,910
LatudaLurasidone Hcl11$36,292
RexultiBrexpiprazole11$21,443
Lurasidone Hcl113$19,178
TrintellixVortioxetine Hydrobromide28$18,562
Aripiprazole155$17,376
Clozapine179$12,491
Paliperidone ErPaliperidone25$10,821
Fluvoxamine Maleate ErFluvoxamine Maleate11$5,041
Bupropion XlBupropion Hcl205$4,556
Quetiapine Fumarate189$3,122
Buspirone Hcl127$2,302
Vilazodone Hcl14$2,152

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo$158$92,66015 claims
Johnson & JohnsonRisperdal Consta$142$58,67328 claims
AbbVieVraylar$391$49,91029 claims
Otsuka America Pharmaceutical, Inc.Rexulti$144$21,44311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 679 psychiatric/mental health providers in Connecticut.

Other psychiatric/mental health in Waterbury

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →